BrainChild Bio, Inc.
BrainChild Bio develops CAR T-cell therapies for central nervous system tumors, prioritizing pediatric brain cancers such as diffuse intrinsic pontine glioma and extending its pipeline to adult tumors including glioblastoma and brain metastases. It aims to create safe and effective treatment options for children and adults with incurable brain tumors.
Facts
- Sectors
- Biotechnology Research
- Employees
- 11–50
- Stage
- Series A
- Founders
- Michael Jensen, MD
Is this your organization? Claim it
Members see BrainChild Bio, Inc.'s funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Michael Jensen Founder, Chief Scientific Officer
-
Steven Brugger Executive, Chief Executive Officer